RPE65 and inherited retinal dystrophy: Following a series of Phase 1 clinical trials [145,146,147,148], the first randomized, controlled Phase 3 clinical trial of gene augmentation therapy for RPE65-mediated inherited retinal dystrophy using AAV2-hRPE65v2 (voretigene neparvovec; LUXTURNA) was conducted [149].